The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.083%)
Open: 48.50
High: 48.50
Low: 48.50
Prev. Close: 48.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

18 Dec 2023 07:00

RNS Number : 0647X
Cambridge Cognition Holdings PLC
18 December 2023
 

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Grant of Options

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that on 15 December 2023, the Company granted options ("Options") over a total of 1,012,465 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") pursuant to the Company's 2022 Long Term Incentive Plan ("LTIP").

Of these Options:

1. Options in respect of 411,449 Ordinary Shares were granted to Persons Discharging Managerial Responsibilities ("PDMRs") as follows:

Name

Role

Number of Ordinary Shares over which Options Granted

Total number of Ordinary Shares over which Options held following Grant

Total number of Ordinary Shares held

Percentage of Current Issued Share Capital Held

Matthew Stork

Chief Executive Officer

190,839

1,185,197

161,450

0.46%

Stephen Symonds

Chief Financial Officer

158,778

311,449

32,950

0.09%

Ricky Dolphin

Chief Technology Officer

61,832

282,359

119,534

0.34%

 

2. Options in respect of 601,016 Ordinary Shares were granted to other employees of the Company.

The Options granted to the PDMRs are in each case "performance share awards" that are exercisable at a price of 1 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, subject to continued service and to the extent to which challenging performance conditions are achieved.

 

Under the terms of the aforementioned performance conditions, one-half of each of the Options is subject to sliding scale compound annual growth rate targets for adjusted revenue over the three year period ending 31 December 2025, the other half of each of the Options is subject to a sliding scale measure of relative total shareholder performance over a three year period that commenced on the grant of the Options.

 

The Options granted to others (save for one more performance share award) are exercisable at a price of 1 pence per Ordinary Share from two and a half years following the date of award until the tenth anniversary of the date of award, and will vest subject to continued service (so called 'restricted share awards').

 

The LTIP has scope to grant both EMI awards and non-EMI awards and was recently adopted by the Board. The terms of the LTIP align to best practice expectations, including as leaver terms and malus and clawback provisions.

 

Following the grant of Options, the total number of options outstanding over unissued Ordinary Shares is 3,311,573 representing approximately 9.47% of the Company's issued share capital.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Names

Matthew Stork - Chief Executive Officer

Stephen Symonds - Chief Financial Officer

Ricky Dolphin - Chief Technology Officer

2.

Reason for the Notification

a)

Position/status

See 1(a) above for positions - all classified as PDMRs of the Company

b)

Initial notification/ Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings plc

b)

LEI

213800SZKDIN122EPA96

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

In each case, the grant of Options over Ordinary Shares on 15 December 2023

 

Identification code

GB00B8DV9647

b)

Nature of the transaction

Grant of Options over Ordinary Shares each with an exercise price of 1 pence per Ordinary Share

 

c)

Price(s) and volume(s)

Price: n/a

Volumes:

Matthew Stork - Options over 190,839 Ordinary Shares

Stephen Symonds - Options over 158,778 Ordinary Shares

Ricky Dolphin - Options over 61,832 Ordinary Shares

d)

Aggregated information:

· Aggregated volume

· Price

 

411,449n/a

e)

Date of the transaction

15 December 2023

f)

Place of the transaction

Outside a trading venue

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Enquiries

Cambridge Cognition Holdings plc

Matthew Stork, Chief Executive Officer

Stephen Symonds, Chief Financial Officer

Tel: 01223 810 700

press@camcog.com

Panmure Gordon (UK) Ltd

(NOMAD and Joint Broker)

 

Tel: 020 78862500

Freddy Crossley / Emma Earl / Mark Rodgers

(Corporate Advisory)

Rupert Dearden

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney/ James Serjeant

Tel: 020 3903 7715

(Corporate Broking)

Hudson Sandler (Financial PR and IR)

Tel: 020 7796 4133

Dan de Belder/Hattie Dreyfus

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBXBDDXDBDGXR
Date   Source Headline
26th Jul 20227:00 amRNSGrant of Options
22nd Jul 202211:05 amRNSSecond Price Monitoring Extn
22nd Jul 202211:00 amRNSPrice Monitoring Extension
22nd Jul 20227:00 amRNSDirector/PDMR Share Purchases
21st Jul 20227:00 amRNSTrading Update and Notice of Results
14th Jul 202211:06 amRNSSecond Price Monitoring Extn
14th Jul 202211:00 amRNSPrice Monitoring Extension
30th Jun 20225:43 pmRNSHolding(s) in Company
8th Jun 20223:14 pmRNSResult of AGM
16th May 20224:35 pmRNSPosting of Annual Report & Notice of AGM
12th Apr 20227:00 amRNSResults for the year ended 31 December 2021
6th Apr 20227:00 amRNSSenior Management Appointments
31st Mar 20227:00 amRNSNotice of Results
29th Mar 20222:06 pmRNSSecond Price Monitoring Extn
29th Mar 20222:00 pmRNSPrice Monitoring Extension
28th Mar 20224:41 pmRNSSecond Price Monitoring Extn
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 20227:00 amRNS£1 million contract for pivotal autoimmune trial
24th Mar 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
4th Feb 202212:06 pmRNSHolding(s) in Company
2nd Feb 20227:00 amRNS£2.1 million contract
27th Jan 20227:00 amRNSTrading Update
10th Jan 20227:00 amRNSNew Major Pharma Client for Schizophrenia Trials
16th Dec 20217:00 amRNSElectronic Clinical Outcomes Assessment Contract
9th Dec 20217:00 amRNS£1.0m Schizophrenia clinical trial contract
22nd Nov 202111:50 amRNSHolding(s) in Company
16th Nov 20217:00 amRNSGrant of Options
2nd Nov 20217:00 amRNSDirectorate Change
26th Oct 20217:00 amRNSContract for pivotal schizophrenia clinical trial
6th Oct 202110:06 amRNSHolding(s) in Company
21st Sep 20217:00 amRNSInterim Results
3rd Aug 20217:00 amRNSTrading Update and Notice of Results
9th Jul 20214:41 pmRNSSecond Price Monitoring Extn
9th Jul 20214:35 pmRNSPrice Monitoring Extension
9th Jul 20217:00 amRNS£1 million contract for late phase cancer trial
1st Jul 20217:00 amRNSSpin-out of Monument Therapeutics
28th Jun 20214:40 pmRNSSecond Price Monitoring Extn
28th Jun 20214:36 pmRNSPrice Monitoring Extension
28th Jun 20212:06 pmRNSSecond Price Monitoring Extn
28th Jun 20212:00 pmRNSPrice Monitoring Extension
28th Jun 202111:05 amRNSSecond Price Monitoring Extn
28th Jun 202111:00 amRNSPrice Monitoring Extension
28th Jun 20217:00 amRNSNew £2.2 million contract
14th Jun 20217:00 amRNS£1.4m of contracts for digital health & wearables
11th Jun 20217:00 amRNSBrain Health Registry Cognitive Assessment Partner
3rd Jun 20213:58 pmRNSHolding(s) in Company
2nd Jun 20217:00 amRNSAppointment of Executive Director
27th May 202112:58 pmRNSResult of AGM and Board Changes
5th May 20217:00 amRNSPosting of Annual Report & Notice of AGM
4th May 202111:52 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.